

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

REGENERON PHARMACEUTICALS, INC.

Petitioner,

v.

NOVARTIS PHARMA AG,  
NOVARTIS TECHNOLOGY LLC,  
NOVARTIS PHARMACEUTICALS CORPORATION,

Patent Owners.

---

Patent Number: 9,220,631

---

**DECLARATION OF DR. SZILÁRD KISS**

# TABLE OF CONTENTS

|   | <b>Page</b> |
|---|-------------|
| <b>I.</b> Introduction.....                         | 1           |
| <b>II.</b> Qualifications and Compensation.....     | 1           |
| <b>III.</b> Relevant Legal Standards .....          | 4           |
| <b>A.</b> Claim Construction .....                  | 4           |
| <b>B.</b> Invalidity .....                          | 5           |
| <b>IV.</b> Person of Ordinary Skill in the Art..... | 7           |
| <b>V.</b> Relevant Technical Background.....        | 9           |
| <b>VI.</b> Obviousness of Claim 24 .....            | 14          |
| <b>VII.</b> Obviousness of Claim 25.....            | 16          |
| <b>VIII.</b> Obviousness of Claim 26.....           | 17          |
| <b>IX.</b> Declaration.....                         | 20          |

## **I. Introduction**

1. I have been retained by Petitioner Regeneron Pharmaceuticals, Inc. (“Petitioner” or “Regeneron”), as an independent expert witness in the above-captioned *inter partes* review (“IPR”), in which Regeneron has requested that the U.S. Patent and Trademark Office cancel as unpatentable all claims of U.S. Patent No. 9,220,631 (“the ’631 patent”). This declaration sets forth my analyses and opinions based on my knowledge, experience, and the materials I have considered.

2. I provide this declaration to explain that certain ophthalmology-related subject matter disclosed and claimed in the ’631 patent was well-known prior to 2012, and also to specifically opine on the obviousness of claims 24-26.

3. For purposes of this declaration, I have assumed that claim 1 of the ’631 patent has separately been shown to be obvious based on the prior art and the Declarations of Horst Koller (Ex. 1003) and James Agalloco (Ex. 1005).

## **II. Qualifications and Compensation**

4. I received my B.A. in Biology from Columbia College in 1997 and my M.D. from Columbia University College of Physicians & Surgeons in 2002. Following graduation from medical school, I was an Intern in the Department of Internal Medicine at St. Luke’s Roosevelt Hospital, Columbia University College of Physicians & Surgeons, from 2002 to 2003. I then became a Resident in the

Ophthalmology Department of the Massachusetts Eye and Ear Infirmary of Harvard Medical School from 2003 to 2006.

5. Including my residency at Harvard, I have over sixteen years of experience in treating patients with ophthalmological diseases. I was certified by the American Board of Ophthalmology in 2007. Following my Residency, I was appointed as a Fellow of the Vitreo-Retinal Service in the Ophthalmology Department of the Massachusetts Eye & Ear Infirmary at Harvard Medical School in 2006 and promoted to Chief Fellow in 2007. In 2008, I became an Assistant Professor of Ophthalmology at Weill Cornell Medical College, and I was promoted to Associate Professor in 2013. I was given the title of Associate Dean of Clinical Compliance in 2019. During this time, I also held a number of other clinical positions. I also hold the title of Vice Chair of Research, Vice Chair of Compliance, Director of Retina Service and Director of Tele-Ophthalmology at Weill Cornell Medical College. I also hold the positions of Associate Attending Physician and Associate Attending Surgeon. My clinical duties involve outpatient evaluation and management for complex vitreo-retinal pathologies such as age-related macular degeneration, diabetic retinopathy, retinal vascular disorders, inherited retinal degenerations, infectious and non-infectious uveitis, and inherited and acquired maculopathies. I also perform surgical management for patients with the above complex vitreo-retinal pathologies.

6. A recent copy of my curriculum vitae (“CV”) is attached as Exhibit 1032 hereto, and provides information about my experience, expertise, and presentations.

7. In addition to my work experience, I have many years of experience participating in professional organizations relating to ophthalmology. Specifically, I am a member of the American Academy of Ophthalmology, the Association for Research in Vision and Ophthalmology, the American Society of Retina Specialists, the Pan-American Association of Ophthalmology, and a number of other professional societies and organizations.

8. In addition to the above, I have given numerous presentations at industry meetings and medical conferences relating to ocular diseases, including wet macular degeneration. These include, for example, a presentation specifically regarding anti-VEGF agents in wet age-related macular degeneration (wet AMD), sustained delivery systems, keratoprosthesis, retinal vein occlusion, uveitis, macular edema secondary to diabetic retinopathy, retinal vein occlusion, and diseases of the vitreomacular interface. I have also performed research on novel drug delivery approaches such as gene therapy, and developed a number of imaging methods. I have authored or co-authored a number of papers, a substantial number of which are listed on the attached CV. I am also on the editorial board of several journals, and I am an *ad hoc* reviewer for other journals and grants.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.